Anti-VEGF antibody

[0001] Antibodies are proteins that bind a specific antigen. Generally, antibodies are specific for their targets, have the ability to mediate immune effector mechanisms, and have a long half-life in serum. Such properties make antibodies powerful therapeutics. Monoclonal antibodies are used therapeutically for the treatment of a variety of conditions including cancer, inflammation, and cardiovascular disease. There are currently over ten therapeutic antibody products on the market and hundreds in development.

[0002] There is a constant need for new antibodies.

[0003] An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody shown in FIG. 1 and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target. In particular embodiments, the CDR regions of the antibody may collectively contain, for example, one, two, three, four, five or up to 10 amino acid differences (e.g., amino acid substitutions, deletions or insertions) relative to the CDR regions of the selected antibody. In certain cases, the CDR regions of a subject antibody may have an amino acid sequence that is defined by a consensus sequence derived from analysis of several related antibodies. In some embodiments the CDR regions of the antibody may be identical to the CDR regions of the selected antibody.

[0004] In particular embodiments, the antibody may comprise: a variable domain comprising: a) a heavy chain variable domain comprising: i. a CDR1 region that is identical in amino acid sequence to the heavy chain CDR1 region of a selected antibody of FIG. 1; ii. a CDR2 region that is identical in amino acid sequence to the heavy chain CDR2 region of the selected antibody; and iii. a CDR3 region that is identical in amino acid sequence to the heavy chain CDR3 region of the selected antibody; and b) a light chain variable domain comprising: i. a CDR1 region that is identical in amino acid sequence to the light chain CDR1 region of the selected antibody; ii. a CDR2 region that is identical in amino acid sequence to the light chain CDR2 region of the selected antibody; and iii. a CDR3 region that is identical in amino acid sequence to the light chain CDR3 region of the selected antibody; wherein the antibody specifically binds a selected target.

[0005] In certain embodiments, an antibody comprising: a) a variable domain comprising: i. a CDR1 region that is identical in amino acid sequence to the heavy chain CDR1 region of a selected antibody of FIG. 1; ii. a CDR2 region that is identical in amino acid sequence to the heavy chain CDR2 region of the selected antibody; and iii. a CDR3 region that is identical in amino acid sequence to the heavy chain CDR3 region of the selected antibody; and b) a light chain variable domain comprising: i. a CDR1 region that is identical in amino acid sequence to the light chain CDR1 region of the selected antibody; ii. a CDR2 region that is identical in amino acid sequence to the light chain CDR2 region of the selected antibody; and iii. a CDR3 region that is identical in amino acid sequence to the light chain CDR3 region of the selected antibody; or b) a variant of the variable domain of part a) that is otherwise identical to the variable domain of part a) except for a number of (e.g., 1, 2, 3, 4, 5, 6, 7 or 8) amino acid substitutions in the CDR regions, where the antibody binds a selected target and, in certain embodiments, the activity of the selected target.

[0006] In certain embodiments, the antibody may comprise the CDRs of a CDR consensus group selected from Table 1. In particular embodiments, the antibody may comprise: a) a heavy chain variable domain comprising: i. a CDR1 region comprising the CDR1 amino acid sequence of a CDR consensus group selected from Table 1; ii. a CDR2 region comprising the CDR2 amino acid sequence of the selected CDR consensus sequence; and iii a CDR3 region comprising the CDR3 amino acid sequence of the selected CDR consensus sequence; and b) a light chain variable domain comprising: i. a CDR1 region comprising the CDR1 amino acid sequence of the selected CDR consensus sequence; ii. a CDR2 region comprising the CDR2 amino acid sequence of the selected CDR consensus sequence; and iii a CDR3 region comprising the CDR3 amino acid sequence of the selected CDR consensus sequence; wherein said antibody specifically binds a selected target and, in certain embodiments, the activity of the selected target.

[0007] A pharmaceutical composition comprising a subject antibody and a pharmaceutically acceptable carrier is also provided.

[0008] A method is also provided. In certain embodiments, the method may comprise contacting a subject antibody with a target of the antibody under conditions suitable for binding of the antibody to the target to produce a complex.

[0009] Also provided is a method of blocking binding of a ligand to its receptor. In certain embodiments, this method may comprise: administering a subject antibody to a subject, wherein said antibody binds to either the receptor or the ligand in said subject and blocks binding of said ligand and its receptor.

[0010] The selected target may be VEGF.

[0012] Before the present subject invention is described further, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0013] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0014] It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an antibody” includes a plurality of such antibodies and reference to “a framework region” includes reference to one or more framework regions and equivalents thereof known to those skilled in the art, and so forth.

[0015] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[0016] The terms “antibody” and “immunoglobulin” are used interchangeably herein. These terms are well understood by those in the field, and refer to a protein consisting of one or more polypeptides that specifically binds an antigen. One form of antibody constitutes the basic structural unit of an antibody. This form is a tetramer and consists of two identical pairs of antibody chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain variable regions are together responsible for binding to an antigen, and the constant regions are responsible for the antibody effector functions.

[0017] The recognized immunoglobulin polypeptides include the kappa and lambda light chains and the alpha, gamma (IgG₁, IgG₂, IgG₃, IgG₄), delta, epsilon and mu heavy chains or equivalents in other species. Full-length immunoglobulin “light chains” (of about 25 kDa or about 214 amino acids) comprise a variable region of about 110 amino acids at the NH₂-terminus and a kappa or lambda constant region at the COOH-terminus. Full-length immunoglobulin “heavy chains” (of about 50 kDa or about 446 amino acids), similarly comprise a variable region (of about 116 amino acids) and one of the aforementioned heavy chain constant regions, e.g., gamma (of about 330 amino acids).

[0018] The terms “antibodies” and “immunoglobulin” include antibodies or immunoglobulins of any isotype, fragments of antibodies which retain specific binding to antigen, including, but not limited to, Fab, Fv, scFv, and Fd fragments, chimeric antibodies, humanized antibodies, single-chain antibodies, and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. The antibodies may be detectably labeled, e.g., with a radioisotope, an enzyme which generates a detectable product, a fluorescent protein, and the like. The antibodies may be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin (member of biotin-avidin specific binding pair), and the like. The antibodies may also be bound to a solid support, including, but not limited to, polystyrene plates or beads, and the like. Also encompassed by the term are Fab′, Fv, F(ab′)₂, and or other antibody fragments that retain specific binding to antigen, and monoclonal antibodies. An antibody may be monovalent or bivalent.

[0019] Antibodies may exist in a variety of other forms including, for example, Fv, Fab, and (Fab′)₂, as well as bi-functional (i.e. bi-specific) hybrid antibodies (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)) and in single chains (e.g., Huston et al., Proc. Natl. Acad. Sci. U.S.A., 85, 5879-5883 (1988) and Bird et al., Science, 242, 423-426 (1988), which are incorporated herein by reference). (See, generally, Hood et al., “Immunology”, Benjamin, N.Y., 2nd ed. (1984), and Hunkapiller and Hood, Nature, 323, 15-16 (1986).

[0020] An immunoglobulin light or heavy chain variable region consists of a “framework” region (FR) interrupted by three hypervariable regions, also called “complementarity determining regions” or “CDRs”. The extent of the framework region and CDRs have been precisely defined (see, “Sequences of Proteins of Immunological Interest,” E. Kabat et al., U.S. Department of Health and Human Services, (1991)). The numbering of all antibody amino acid sequences discussed herein conforms to the Kabat system. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs. The CDRs are primarily responsible for binding to an epitope of an antigen.

[0021] Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from antibody variable and constant region genes belonging to different species. For example, the variable segments of the genes from a non-human monoclonal antibody may be joined to human constant segments, such as gamma 1 and gamma 3. An example of a therapeutic chimeric antibody is a hybrid protein composed of the variable or antigen-binding domain from a rabbit antibody and the constant or effector domain from a human antibody (e.g., the anti-Tac chimeric antibody made by the cells of A.T.C.C. deposit Accession No. CRL 9688), although other mammalian species may be used.

[0022] As used herein, the term “humanized antibody” or “humanized immunoglobulin” refers to an non-human (e.g., mouse or rabbit) antibody containing one or more amino acids that have been substituted with a correspondingly positioned amino acid from a human antibody. In some cases, humanized antibodies produce a reduced immune response in a human host, as compared to a non-humanized version of the same antibody.

[0023] It is understood that the humanized antibodies designed and produced by the present method may have amino acid substitutions which have substantially no effect on antigen binding or other antibody functions.

[0024] “Similar amino acids” defined as follows: gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr. In other words, gly and ala are similar amino acids; val, ile and leu are similar amino acids; asp and glu are similar amino acids; asn and gln are similar amino acids; ser and thr are similar amino acids; lys and arg are similar amino acids; and phe and tyr are similar amino acids. Substituting an amino acid for a similar amino acid is termed a “conservative amino acid substitution” herein. Amino acids that are not present in the same group as set forth above are “dis-similar” amino acids.

[0025] The term “specific binding” refers to the ability of an antibody to preferentially bind to a particular analyte that is present in a homogeneous mixture of different analytes. In certain embodiments, a specific binding interaction will discriminate between desirable and undesirable analytes in a sample, in some embodiments more than about 10 to 100-fold or more (e.g., more than about 1000- or 10,000-fold).

[0026] In certain embodiments, the affinity between an antibody and its target when they are specifically bound in a capture agent/analyte complex is characterized by a KD (dissociation constant) of less than 10⁻⁶ M, less than 10⁻⁷ M, less than 10⁻⁸ M, less than 10⁻⁹ M, less than 10⁻⁹ M, less than 10⁻¹¹ M, or less than about 10⁻¹² M or less.

[0027] A “variable region” of a heavy or light antibody chain is an N-terminal mature domain of the chains. All domains, CDRs and residue numbers are assigned on the basis of sequence alignments and structural knowledge. Identification and numbering of framework and CDR residues is as described in by Kabat, Chothia (Chothia, Structural determinants in the sequences of immunoglobulin variable domain. J Mol Biol 1998;278:457-79) and others.

[0028] VH is the variable domain of an antibody heavy chain. VL is the variable domain of an antibody light chain, which could be of the kappa (K) or of the lambda isotype. K-1 antibodies have the kappa-1 isotype whereas K-2 antibodies have the kappa-2 isotype and Vλ is the variable lambda light chain.

[0029] As used herein, the terms “determining,” “measuring,” and “assessing,” and “assaying” are used interchangeably and include both quantitative and qualitative determinations.

[0030] The terms “polypeptide” and “protein”, used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. The term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins; fusion proteins with detectable fusion partners, e.g., fusion proteins including as a fusion partner a fluorescent protein, β-galactosidase, luciferase, etc.; and the like. Polypeptides may be of any size, and the term “peptide” refers to polypeptides that are 8-50 residues (e.g., 8-20 residues) in length.

[0031] As used herein the term “isolated,” when used in the context of an isolated antibody, refers to an antibody of interest that is at least 60% free, at least 75% free, at least 90% free, at least 95% free, at least 98% free, and even at least 99% free from other components with which the antibody is associated with prior to purification.

[0032] The terms “treatment” “treating” and the like are used herein to refer to any treatment of any disease or condition in a mammal, e.g. particularly a human or a mouse, and includes: a) preventing a disease, condition, or symptom of a disease or condition from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; b) inhibiting a disease, condition, or symptom of a disease or condition, e.g., arresting its development and/or delaying its onset or manifestation in the patient; and/or c) relieving a disease, condition, or symptom of a disease or condition, e.g., causing regression of the condition or disease and/or its symptoms.

[0033] The terms “subject,” “host,” “patient,” and “individual” are used interchangeably herein to refer to any mammalian subject for whom diagnosis or therapy is desired, particularly humans. Other subjects may include cattle, dogs, cats, guinea pigs, rabbits, rats, mice, horses, and so on.

[0034] “Corresponding amino acids”, are amino acid residues that are at an identical position (i.e., they lie across from each other) when two or more amino acid sequences are aligned. Methods for aligning and numbering antibody sequences are set forth in great detail in Kabat supra, and others. As is known in the art (see, e.g. Kabat 1991 Sequences of Proteins of Immunological Interest, DHHS, Washington, D.C.), sometimes one, two or three gaps and/or insertions of up to one, two, three or four residues, or up to about 15 residues (particularly in the L3 and H3 CDRs) may be made to one or both of the amino acids of an antibody in order to accomplish an alignment.

[0035] A “natural” antibody is an antibody in which the heavy and light immunoglobulins of the antibody have been naturally selected by the immune system of a multi-cellular organism, as opposed to unnaturally paired antibodies made by e.g. phage display, or humanized antibodies. As such, certain antibodies do not contain any viral (e.g., bacteriophage M13)-derived sequences. Spleen, lymph nodes and bone marrow are examples of tissues that produce natural antibodies.

[0036] A “parent” antibody is an antibody is the target of amino acid substitutions. In certain embodiments, amino acids may be “donated” by a “donor” antibody to the parent antibody to produce an altered antibody.

[0037] “Related antibodies” are antibodies that have a similar sequence and produced by cells that have a common B cell ancestor. Such a B cell ancestor contains a genome having a rearranged light chain VJC region and a rearranged heavy chain VDJC region, and produces an antibody that has not yet undergone affinity maturation. “Naïve” or “virgin” B cells present in spleen tissue, are exemplary B cell common ancestors. Related antibodies bind to the same epitope of an antigen and are typically very similar in sequence, particularly in their L3 and H3 CDRs. Both the H3 and L3 CDRs of related antibodies have an identical length and a near identical sequence (e.g., differ by 0-4 residues). Related antibodies are related via a common antibody ancestor, the antibody produced in the naive B cell ancestor. The term “related antibodies” is not intended to describe a group of antibodies that do not have a common antibody ancestor produced by a B-cell. In certain cases, related antibodies: i. bind to the same antigen; ii. each comprise heavy chain variable domains that have an overall amino acid sequence identity of at least 90% relative to one another; iii. each comprise light chain variable domains that have an overall amino acid sequence identity of at least 90% relative to one another; iv. have H3 CDRs that are identical in length and identical in sequence except for 0, 1 or 2 amino acid substitutions relative to one another; and v. have L3 CDRs that are identical in length and identical in sequence except for 0, 1 or 2 amino acid substitutions relative to one another;

[0038] A “blocking antibody”, “neutralizing antibody” or “antibody that neutralizes” or any grammatical equivalent thereof refers to an antibody whose binding to a target results in inhibition binding to a target or of a biological activity of the target e.g., by at least about 20%, 30%, 40%, 50%, 80%, 95% or 99%. This inhibition of the biological activity of a target can be assessed by measuring one or more indicators of the target's biological activity, such as activation of a signal transduction pathway, binding, or cellular changes effected by the target. The biological activity of the targets described herein can be assessed by one or more of several standard in vitro or in vivo assays known in the art.

[0039] The term “VEGF” or its non-abbreviated form “vascular endothelial growth factor”, as used herein, refers the protein products encoded by the VEGF gene. VEGF is involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors (the VEGFRs) on the cell surface, causing them to dimerize and become activated through transphosphorylation. The VEGF receptors have an extracellular portion containing 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. VEGF, its biological activities, and its receptors are well studied and are described in Matsumoto et al (VEGF receptor signal transduction Sci STKE. 2001:RE21 and Marti et al (Angiogenesis in ischemic disease. Thromb Haemost. 1999 Suppl 1:44-52). The term VEGF is intended to include recombinant VEGF molecules, which can be prepared by standard recombinant expression methods or purchased commercially (R & D Systems, Catalog No. 210-TA, Minneapolis, Minn.), as well as fusion proteins containing a VEGF molecule. Amino acid sequences of exemplary VEGFs that may be employed herein are found in the NCBI's Genbank database and a full description of human VEGF and its role in various diseases and conditions is found in NCBI's Online Mendelian Inheritance in Man database.

[0040] An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody shown in FIG. 1 and b) a light chain variable domain that comprises CDR regions that are substantially identical to the light chain CDR regions of the selected antibody, where the antibody binds a selected target. In particular embodiments, the CDR regions of the antibody may collectively contain, for example, one, two, three, four, five up to 10 amino acid differences (e.g., amino acid substitutions, deletions or insertions) relative to the CDR regions of the selected antibody. In some embodiments the CDR regions of the antibody may be identical to the CDR regions of the selected antibody. As would be readily apparent, such an antibody further contains framework sequences that position the CDRs.

[0041] In particular embodiments, a subject antibody may have: a) a heavy chain variable domain having an amino acid sequence that is at least 80% identical (e.g., at least 90%, at least 95% or at least 98% or 99% identical) to the heavy chain variable domain of a selected antibody shown in FIG. 1 and b) a light chain variable domain having an amino acid sequence that is at least 80% identical (e.g., at least 90%, at least 95% or at least 98% or 99% identical) to the light chain variable domain of the selected antibody.

[0042] In particular embodiments, the antibody may comprise: a) a heavy chain variable domain comprising: i. a CDR1 region that is identical in amino acid sequence to the heavy chain CDR1 region of a selected antibody of FIG. 1; ii. a CDR2 region that is identical in amino acid sequence to the heavy chain CDR2 region of the selected antibody; and iii. a CDR3 region that is identical in amino acid sequence to the heavy chain CDR3 region of the selected antibody; and b) a light chain variable domain comprising: i. a CDR1 region that is identical in amino acid sequence to the light chain CDR1 region of the selected antibody; ii. a CDR2 region that is identical in amino acid sequence to the light chain CDR2 region of the selected antibody; and iii. a CDR3 region that is identical in amino acid sequence to the light chain CDR3 region of the selected antibody; wherein the antibody specifically binds a selected target.

[0043] Immunization of a rabbit with a single antigen yields multiple antibodies that can be grouped by the relatedness of their sequence. The antibodies within each group are related to each other in that they are produced by cells that have a common naive B cell ancestor. The antibody produced by the ancestral B cell does has not yet undergone affinity maturation, whereas the related antibodies have undergone affinity maturation and the final stage of B-cell development and have “evolved” from the common B-cell ancestor antibody in that they contain amino acid substitutions caused by somatic hypermutation, gene conversion and other cellular mutation events that occur during affinity maturation.

[0044] The amino acid sequence of related antibodies can be compared (e.g., by aligning those sequences), and the antibodies are classified according to their similarity to each other to identify related groups of antibodies. The antibodies of a group of related antibodies generally contain a near identical sequence, have CDR regions that are identical in length, and have differences in amino acid sequence in the framework and/or CDR regions. These differences indicate amino acids that can be substituted in either of the related antibodies. In certain cases, the amino acids at a position may be dis-similar amino acids, in which case an amino acid at that position may be substituted with any other amino acid, for example. In other cases, the amino acids at a position may be similar amino acids, in which case an amino acid at that position may be substituted with a similar amino acid, where a similar amino acid is defined above. In certain cases, the amino acid may be substituted from one related antibody to another, if the amino acid is different.

[0045] Since each of the CDRs of a particular consensus group were originally produced and effectively tested by the immune system of the immunized animal, substituting one amino acid for another consensus amino acid should be well tolerated by the antibody. The antibodies of FIG. 1 were aligned, groups of related antibodies were identified, and consensus sequences were identified. In certain cases, an antibody may comprise the CDRs of a CDR consensus group, where the CDR consensus groups are derived from sequence alignments of related antibodies. The consensus sequences of the antibodies of FIG. 1 are shown in Table 1. Table 1 indicates substitutable positions in a subject antibody, where a substitution may be to any other amino acid, a similar amino acid (i.e., a conservative amino acid substitution), or from one antibody to another, for example. Such methods are further described in U.S. patent application Ser. No. 10/984,473 (published as US-2006-0099204), which is incorporated by reference for disclosure of those methods.

[0046] In certain embodiments, the antibody may comprise the CDRs of a CDR consensus group selected from Table 1. In particular embodiments, the antibody may comprise: a) a heavy chain variable domain comprising: i. a CDR1 region comprising the CDR1 amino acid sequence of a CDR consensus group selected from Table 1; ii. a CDR2 region comprising the CDR2 amino acid sequence of the selected CDR consensus sequence; and iii a CDR3 region comprising the CDR3 amino acid sequence of the selected CDR consensus sequence; and b) a light chain variable domain comprising: i. a CDR1 region comprising the CDR1 amino acid sequence of the selected CDR consensus sequence; ii. a CDR2 region comprising the CDR2 amino acid sequence of the selected CDR consensus sequence; and iii a CDR3 region comprising the CDR3 amino acid sequence of the selected CDR consensus sequence; wherein said antibody specifically binds a selected target.

[0047] For example, such an antibody may comprise: a) a heavy chain variable domain having: i. a CDR1 of the formula: NNA/DVMC (SEQ ID NO:77), a CDR2 of the formula: CIMTTDVVTE/AYANWAKS (SEQ ID NO:78), and a CDR3 of the formula: DSVGSPLMSFDL (SEQ ID NO:79), and; b) a light chain variable domain having: a CDR1 of the formula: QASQN/SL/VYN/GNNELS (SEQ ID NO:80), a CDR2 of the formula: W/RASTLAS (SEQ ID NO:81) and a CDR3 of the formula: A/S/GGYKSYS/YND/GGN/SG (SEQ ID NO:82), where the antibody blocks VEGF.

[0048]

TABLE 1
HEAVY CHAIN
CDR
Consensus				SEQ		SEQ		SEQ
groups	Activity	Antibody	CDR 1	ID NO.	CDR 2	ID NO.	CDR 3	ID NO.
I	VEGF binding	2, 7, 20, 21, 23	NNA/DVMC	77	CIMTTDVVTE/AY	78	DSVGSPLMSFDL	79
					ANWAKS
II	VEGF binding	1, 4, 8	SS/N/GYY/DMC	83	CIYTGSN/GN/RTY/HYA	84	A/GI/NSINVYV/	85
					Y/SWG/AKG		A/GL/V
III	VEGF binding	3, 13	SSYNM/IC	89	CIHGGD/SDGTTY	90	DEWAGTRLK/NL	91
					YATWAKG
IV	VEGF binding	R1, R19, R13,	T/S/I/VYEG/MS/N	95	Y/VIYT/P/SDS/	96	G/TDLS/NS/TGW	97
		R33			GD/STVYAT/SWA		GAA/N/DL
					KG
V	VEGF binding	R2, R4, R9, R14	NYYWN	101	FIDLLGSADYASWAKG	102	SGSH/SSGWG/CA	103
							DI
VI	VEGF binding	R10, R31	SYYMN	107	FID FS/GSDAYY	108	SGVDSA/GWGFDL	109
					ANWAKG
VII	VEGF binding	R7, R16, R18	SYDM/II	113	YIDA/TV/IGSS	114	GDWSTAWGFNL	115
					T/RYYASWAKG
VIII	VEGF binding	R8, R15, R30	SYAV/MS	119	IIS/TSSG/VS/I	120	DAN/SSR/TGYYI	121
					TYYASWAKG		PYYFNI
IX	VEGF binding	R23, R24	SYAMG	125	IIYLETGNTYYAT	126	GSWSDYAL	127
					WAKG
LIGHT CHAIN
CDR
Consensus				SEQ		SEQ		SEQ
groups	Activity	Antibody	CDR1	ID NO.	CDR2	ID NO.	CDR3	ID NO.
I	VEGF binding	2, 7, 20, 21, 23	QASQN/SL/VYN/GNNEL	80	W/RASTLAS	81	A/S/GGYKSYS/Y	82
			S				ND/GGN/SG
II	VEGF binding	1, 4, 8	QASQSID/GN/SSLT/A	86	R/GAST/NLE/AS	87	QGYYW/YG/SS/D	88
							T/A/SAD/ENA
III	VEGF binding	3, 13	QASET/SINT/SF/WLS	92	QASTLAS	93	QSYFYG/KSGN/S	94
							YGFV/I
IV	VEGF binding	R-1, R19, R13,	QASEN/SIR/SS/NWLA	98	QASK/S/RLAS	99	QNC/SYS/RFST/	100
		R33					A/S/IYGA/GA
V	VEGF binding	R2, R4, R9, R14	QASQSIN/ST/SWLS	104	QASKLAS	105	QNNYLMATYGGP	106
VI	VEGF binding	R10, R31	QASQSIRSWLA	110	EASKLAF	111	QNS/DYGWTSYGA	112
							T
VII	VEGF binding	R7, R16, R18	QASQSISGWLS	116	QASKLAS	117	QSVYLI/VSTYGA	118
							T
VIII	VEGF binding	R8, R15, R30	QASESIYSNLA	122	AAS/FYLAS	123	QSAH/NYSSSGDI	124
							A
IX	VEGF binding	R23, R24	QSSQNVYSNDLLS	128	EASKLAS	129	AGAYSGNINV	130

[0049] In a particular embodiment, the antibody may comprise: a) a heavy chain variable domain comprising CDRs comprising an amino acid sequence of the formulae: CDR 1: (S/N)(N/S/-) YXM(C/N/S/I); CDR2: (C/F/Y/I)I(M/Y/D/S)(T/-)(G/-)XXXX(T/A)(Y/E/D/V) YA(N/S/T)WAK(G/S) (SEQ ID NO:131); CDR3: (G/D/S)(S/D/G/A)XXXX(L/W/Y/-)(X/-)(X/-) (X/-)(X/-)(Y/G/S/-)(F/A/Y/-)(A/N/D)(L/I), and; b) a light chain variable domain comprising CDRs comprising an amino acid sequence of the formulae: CDR1: Q(A/S)S(E/Q)(S/N)(L/V/I)X(S/N/G/-)(N/D/-)(N/T/S/D/G)XL(S/T/A); CRD2: XAS(T/K/Y)L(A/E)S (SEQ ID NO:132); CDR3: (A/Q)(G/N/S)X(Y/K)XXXX(XI-) (G/D/-)(X/-) (X/-)X(G/T/A/P/V), wherein X is any amino acid, - denotes no residue, / denotes alternative amino acid present at a position, and ( ) denotes one amino acid position. This antibody blocks VEGF.

Modified Antibodies

[0050] The above-described antibodies may modified by substituting, adding, or deleting at least one amino acid. In one embodiment, an above-described the amino acid sequence of a subject antibody is modified to provide a humanized antibody for human therapeutic use, or another type of modified antibody. In general, these modified antibodies have the general characteristics of the above-described rabbit antibodies and contain at least the CDRs of an above-described rabbit antibody, or, in certain embodiments, CDRs that are very similar to the CDRs of an above-described rabbit antibody.

Humanized Antibodies

[0051] In one embodiment, therefore, the invention provides humanized versions of the above-described antibodies. In general, humanized antibodies are made by substituting amino acids in the framework regions of a parent non-human antibody to produce a modified antibody that is less immunogenic in a human than the parent non-human antibody. Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,332). In certain embodiments, framework substitutions are identified by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions (see, e.g., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988)). Additional methods for humanizing antibodies contemplated for use in the present invention are described in U.S. Pat. Nos. 5,750,078; 5,502,167; 5,705,154; 5,770,403; 5,698,417; 5,693,493; 5,558,864; 4,935,496; and 4,816,567, and PCT publications WO 98/45331 and WO 98/45332. In particular embodiments, a subject rabbit antibody may be humanized according to the methods set forth in published U.S. patent applications 20040086979 and 20050033031. Accordingly, the antibodies described above may be humanized using methods that are well known in the art.

[0052] In one embodiment of particular interest, a subject antibody may be humanized in accordance with the methods set forth in great detail in U.S. patent application Ser. No. 10/984,473, filed on Nov. 8, 2004 and entitled “Methods for antibody engineering”, which application is incorporated by reference in its entirety. In general, this humanization method involves identifying a substitutable position of an antibody by comparing sequences of antibodies that bind to the same antigen, and replacing the amino acid at that position with a different amino acid that is present at the same position of a similar human antibody. In these methods, the amino acid sequence of a parental rabbit antibody is compared to (i.e., aligned with) the amino acid sequences of other related rabbit antibodies to identify variation tolerant positions. The amino acid sequence of the variable domain of the parental rabbit antibody is usually compared to a database of human antibody sequences, and a human antibody that has an amino acid sequence that is similar to that of the parental antibody is selected. The amino acid sequences of the parental antibody and the human antibody are compared (e.g., aligned), and amino acids at one or more of the variation tolerant positions of the parental antibody are substituted by correspondingly positioned amino acids in the human antibody. In this humanization method, the CDR regions of the antibody may be humanized in addition to the framework regions.

[0053] The above-discussed variation tolerant position substitution methods are readily incorporated into any known humanization method and are also readily employed to produce humanized antibodies containing CDR regions that are altered with respect to the CDR regions of the parent antibody. Accordingly humanized antibodies containing altered versions of the CDRs of the above-described antibodies are provided.

[0054] As noted above, the subject antibody may be modified to provide a modified antibody. In particular embodiments, this method include making one or more amino acid substitutions (e.g., one, up to two, up to three, up to four or up to five of more, usually up to 10 or more). An amino acid substitution may be at any position, and the amino acid at that position may be substituted by an amino acid of any identity. In certain embodiments, a modified antibody may have the same general characteristics of the above-described rabbit antibodies. In one embodiment, after a substitutable position has been identified using the methods of U.S. Ser. No. 10/984,473, the amino acids at that position may be substituted. In particular embodiments, an amino acid substitution may be a humanizing substitution (i.e., a substitution that make the amino acid sequence more similar to that of a human antibody), a directed substitution (e.g., a substitution that make the amino acid sequence of an antibody more similar to that of a related antibody in the same group), a random substitution (e.g., a substitution with any of the 20 naturally-occurring amino acids) or a conservative substitution (e.g., a substitution with an amino acid having biochemical properties similar to that being substituted).

[0055] In certain embodiments, modified antibodies of the invention may contain a heavy or light chain that is encoded by a polynucleotide that hybridizes under high stringency conditions to a rabbit heavy or light chain-encoding nucleic acid. High stringency conditions include incubation at 50° C. or higher in 0.1×SSC (15 mM saline/0.15 mM sodium citrate).

[0056] In certain embodiments, modified antibodies of the invention may contain a heavy or light chain that is encoded by a polynucleotide that is at least 80% identical to (e.g., at least 85%, at least 90%, at least 95%, at least 98%) a rabbit heavy or light chain-encoding nucleic acid. The percentage identity is based on the shorter of the sequences compared. Well known programs such as BLASTN (2.0.8) (Altschul et al. (1997) Nucl. Acids. Res. 25:3389-3402) using default parameters and no filter may be employed to make a sequence comparison.

Methods of Use

[0057] The above-described antibodies may be employed in a variety of methods. One such method comprises: contacting a subject antibody with a target of the antibody under conditions suitable for binding of the antibody to the target to produce a complex. Such a method may be performed by ELISA or western blotting, or by any one of many immunological detection methods known in the art, for example. In other embodiments, a method of blocking binding of a ligand to its receptor is provided. In these embodiments, the method comprises: administering a subject antibody to a subject, where the antibody binds to either the receptor or the ligand in said subject and blocks binding thereof.

[0058] A subject antibody inhibits at least one activity of its target in the range of about 20% to 100%, e.g., by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, usually up to about 70%, up to about 80%, up to about 90% or more. In certain assays, a subject antibody may inhibits its target with an IC₅₀ of 1×10⁻⁷ M or less (e.g., 1×10⁻⁷ M or less, 1×10⁻⁸ M or less, 1×10⁻⁹ M or less, usually to 1×10⁻¹² M or 1×10⁻¹³ M). In assays in which a mouse is employed, a subject antibody may have an ED₅₀ of less then 1 μg/mouse (e.g., 10 ng/mouse to about 1 μg/mouse).

[0059] The protocols that may be employed in these methods are numerous, and include but are not limited to cell-free assays, e.g., binding assays; cellular assays in which a cellular phenotype is measured, e.g., gene expression assays; and in vivo assays that involve a particular animal (which, in certain embodiments may be an animal model for a condition related to the target). In certain cases, the assay may be a vascularization assay.

[0060] In certain embodiments, a subject antibody may be contacted with a cell in the presence of VEGF, and a VEGF response phenotype of the cell monitored.

[0061] Exemplary VEGF assays include assays using isolated protein in a cell free systems, in vitro using cultured cells or in vivo assays. Exemplary VEGF assays include, but are not limited to a receptor tyrosine kinase inhibition assay (see, e.g., Cancer Research Jun. 15, 2006; 66:6025-6032), an in vitro HUVEC proliferation assay (FASEB Journal 2006; 20: 2027-2035), an in vivo solid tumor disease assay (U.S. Pat. No. 6,811,779) and an in vivo angiogenesis assay (FASEB Journal 2006; 20: 2027-2035). These assays are well known in the art. The descriptions of these assays are hereby incorporated by reference.

[0062] Exemplary TNF-α assays include in vitro assays using cell free systems or using cultured cells or in vivo assays. As such, TNF-α assays include in vitro human whole blood assay and cell mediated cytotoxicity assay (U.S. Pat. No. 6,090,382 ), in vitro tumor human killing assay (see, e.g., published U.S. patent application 20040185047), in vivo tumor regression assay (USP Application 20040002589). Additional TNF-α assays are described in a variety of publications, including 20040151722, 20050037008, 20040185047, 20040138427, 20030187231, 20030199679, and Balazovich (Blood 1996 88: 690-696).

Methods for Producing Antibodies

[0063] In many embodiments, the nucleic acids encoding a subject monoclonal antibody are introduced directly into a host cell, and the cell incubated under conditions sufficient to induce expression of the encoded antibody. The antibodies of this invention are prepared using standard techniques well known to those of skill in the art in combination with the polypeptide and nucleic acid sequences provided herein. The polypeptide sequences may be used to determine appropriate nucleic acid sequences encoding the particular antibody disclosed thereby. The nucleic acid sequence may be optimized to reflect particular codon “preferences” for various expression systems according to standard methods well known to those of skill in the art.

[0064] Any cell suitable for expression of expression cassettes may be used as a host cell. For example, yeast, insect, plant, etc., cells. In many embodiments, a mammalian host cell line that does not ordinarily produce antibodies is used, examples of which are as follows: monkey kidney cells (COS cells), monkey kidney CVI cells transformed by SV40 (COS-7, ATCC CRL 165 1); human embryonic kidney cells (HEK-293, Graham et al. J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); chinese hamster ovary-cells (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. (USA) 77:4216, (1980); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CVI ATCC CCL 70); african green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL 51); TRI cells (Mather et al., Annals N. Y. Acad. Sci 383:44-68 (1982)); NIH/3T3 cells (ATCC CRL-1658); and mouse L cells (ATCC CCL-1). Additional cell lines will become apparent to those of ordinary skill in the art. A wide variety of cell lines are available from the American Type Culture Collection, 10801 University Boulevard, Manassas, Va. 20110-2209.

[0065] Methods of introducing nucleic acids into cells are well known in the art. Suitable methods include electroporation, particle gun technology, calcium phosphate precipitation, direct microinjection, and the like. The choice of method is generally dependent on the type of cell being transformed and the circumstances under which the transformation is taking place (i.e. in vitro, ex vivo, or in vivo). A general discussion of these methods can be found in Ausubel, et al, Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995. In some embodiments lipofectamine and calcium mediated gene transfer technologies are used.

[0066] After the subject nucleic acids have been introduced into a cell, the cell is typically incubated, normally at 37° C., sometimes under selection, for a period of about 1-24 hours in order to allow for the expression of the antibody. In most embodiment, the antibody is typically secreted into the supernatant of the media in which the cell is growing in.

[0067] In mammalian host cells, a number of viral-based expression systems may be utilized to express a subject antibody. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

[0068] For long-term, high-yield production of recombinant antibodies, stable expression may be used. For example, cell lines, which stably express the antibody molecule, may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with immunoglobulin expression cassettes and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into a chromosome and grow to form foci which in turn can be cloned and expanded into cell lines. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

[0069] Once an antibody molecule of the invention has been produced, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In many embodiments, antibodies are secreted from the cell into culture medium and harvested from the culture medium.

Formulations and Administration

[0070] The antibodies of the invention may be administered in any manner which is medically acceptable. This may include injections, by parenteral routes such as intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumor, intraperitoneal, intraventricular, intraepidural, or others as well as oral, nasal, ophthalmic, rectal, or topical. Sustained release administration is also specifically included in the invention, by such means as depot injections or erodible implants. Localized delivery is particularly contemplated, by such means as delivery via a catheter to one or more arteries, such as the renal artery or a vessel supplying a localized tumor.

[0071] The subject antibodies may be formulated with a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” means one or more organic or inorganic ingredients, natural or synthetic, with which the antibody is combined to facilitate its application. A suitable carrier includes sterile saline although other aqueous and non-aqueous isotonic sterile solutions and sterile suspensions known to be pharmaceutically acceptable are known to those of ordinary skill in the art. An “effective amount” refers to that amount which is capable of ameliorating or delaying progression of the diseased, degenerative or damaged condition. An effective amount can be determined on an individual basis and will be based, in part, on consideration of the symptoms to be treated and results sought. An effective amount can be determined by one of ordinary skill in the art employing such factors and using no more than routine experimentation.

[0072] In one embodiment a subject antibody is administered to a patient by intravenous, intramuscular or subcutaneous injection. An antibody may be administered within a dose range between about 0.1 mg/kg to about 100 mg/kg; between about 1 mg/kg to 75 mg/kg; or about 10 mg/kg to 50 mg/kg. The antibody may be administered, for example, by bolus injunction or by slow infusion. Slow infusion over a period of 30 minutes to 2 hours may be used.

Utility

[0073] A subject antibody is useful for treating a disorder relating to its target.

[0074] In one embodiment, the invention provides a method of treating a subject for a VEGF-related condition. The method generally involves administering a subject antibody to a subject having a VEGF -related disorder in an amount effective to treat at least one symptom of the VEGF-related disorder. VEGF-related conditions are generally characterized by excessive vascular endothelial cell proliferation, vascular permeability, edema or inflammation such as brain edema associated with injury, stroke or tumor; edema associated with inflammatory disorders such as psoriasis or arthritis, including rheumatoid arthritis; asthma; generalized edema associated with burns; ascites and pleural effusion associated with tumors, inflammation or trauma; chronic airway inflammation; capillary leak syndrome; sepsis; kidney disease associated with increased leakage of protein; and eye disorders such as age related macular degeneration and diabetic retinopathy. Such conditions include breast, lung, colorectal and renal cancer.

Kits

[0075] Also provided by the subject invention are kits for practicing the subject methods, as described above. The subject kits at least include one or more of: a subject antibody, a nucleic acid encoding the same, or a cell containing the same. The subject antibody may be humanized. Other optional components of the kit include: buffers, etc., for administering the antibody or for performing an activity assay. The nucleic acids of the kit may also have restrictions sites, multiple cloning sites, primer sites, etc to facilitate their ligation to non-rabbit antibody nucleic acids. The various components of the kit may be present in separate containers or certain compatible components may be precombined into a single container, as desired.

[0076] In addition to above-mentioned components, the subject kits typically further include instructions for using the components of the kit to practice the subject methods. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

[0077] Also provided by the subject invention are kits including at least a computer readable medium including programming as discussed above and instructions. The instructions may include installation or setup directions. The instructions may include directions for use of the invention with options or combinations of options as described above. In certain embodiments, the instructions include both types of information.

[0078] Providing the software and instructions as a kit may serve a number of purposes. The combination may be packaged and purchased as a means for producing rabbit antibodies that are less immunogenic in a non-rabbit host than a parent antibody, or nucleotide sequences thereof.

[0079] The instructions are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging), etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g., CD-ROM, diskette, etc, including the same medium on which the program is presented.

[0080] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

[0081] The antibody were obtained from rabbit hybridoma producing antibodies that block the interaction of VEGF with its receptor (VEGF-R2). The hybridoma were generated by fusing immunized rabbit splenocytes with the rabbit hybridoma fusion partner 240E-W2.

[0082] Rabbits were immunized with an Fc fusion protein. To express the fusion protein, the human VEGF165 coding sequence was cloned into the C-terminal of rabbit IgG Fc which contains the signal peptide sequence of rabbit IgG heavy chain at its N-terminus. The fusion protein was produced in HEK 293 cells and secreted into the culture medium. To obtain the pure protein for immunization, the supernatant was harvested and purified through a protein A column. The eluted protein was dialyzed against PBS buffer.

[0083] New Zealand white rabbits were immunized with the immunogen. Each rabbit received a primary immunization by subcutaneous injection of 0.4 mg of the purified protein with complete Freund's or TiterMax adjuvant. The animals were then boosted by subcutaneous injection of 0.2 mg of the protein with incomplete Freund's or TiterMax once every three weeks. The final boost (0.4 mg protein in saline) was given intravenously 4 days before splenectomy.

[0084] Cell fusions were performed following the conventional protocol of Spieker-Polet using PEG. The ratio of splenocytes to the fusion partner was 2:1. The fused cells were plated in 96-well plates and HAT was added after 48 hrs to select for hybridomas.

[0085] Direct ELISA was performed to identify antibodies that block binding of VEGF to a VEGF-R2 fusion protein coated onto a microtiter plate. Antibodies identified in this assay were then were screened for blocking VEGF interaction with its receptor in a ligand-receptor assay. The blocking antibodies were identified by their inhibition of binding of Fc-VEGF-R2 (Extracellular domain) or VEGF-Fc in solution to Fc-VEGF or Fc-VEGF-R2 coated on plates.

[0086] cDNAs coding the heavy and light chains of the antibodies were cloned and sequenced.